Immuno-Oncology Market Player, Imugene Delivers Remarkable Performance In FY 2019

Immuno-Oncology Market Player, Imugene Delivers Remarkable Performance In FY 2019

Clinical stage immuno-oncology firm headquartered in Australia, Imugene Limited (ASX: IMU) is engaged in the development of a wide range of new treatments that...

A Deep Dive into Imugene’s Opportunities in the Immuno-oncology Market

Imugene Limited (ASX: IMU) is a clinical stage biotechnology company that focuses on the development of immunotherapies that have the potential to enable a...

Imugene Goes Great Guns with Strong Management Team

Imugene Limited (ASX: IMU), an Australian-headquartered clinical-stage immuno-oncology company, focusses on the development of emerging immunotherapies to enhance the efficacy of cancer treatments. The...

A Glance at Imugene’s B-Cell Vaccine Developments in 2019

An Australian-headquartered clinical stage biotechnology company, Imugene Limited (ASX: IMU) seeks to develop different novel immunotherapies to boost the efficacy of cancer treatments. Imugene’s...

Imugene Releases Bioshares Presentation and Quarterly Updates; Stock Zooms up

An emerging leader in cancer immuno-oncology, Imugene Limited (ASX: IMU) is a clinical stage biotechnology company seeking to develop a range of novel immunotherapies...
5,632FansLike
2,652FollowersFollow
455SubscribersSubscribe

Latest News

Editorial